4.7 Article

Substrate Specificity and Oligomerization of Human GMP Synthetase

Journal

JOURNAL OF MOLECULAR BIOLOGY
Volume 425, Issue 22, Pages 4323-4333

Publisher

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jmb.2013.06.032

Keywords

GMP synthetase; crystal structure; amidotransferase; substrate specificity

Funding

  1. Swedish Research Council
  2. Swedish Cancer Society
  3. Canadian Institutes for Health Research [1097737]
  4. Canadian Foundation for Innovation
  5. Genome Canada through the Ontario Genomics Institute
  6. GlaxoSmithKline
  7. Karolinska Institutet
  8. Knut and Alice Wallenberg Foundation
  9. Ontario Innovation Trust
  10. Ontario Ministry for Research and Innovation
  11. Merck Co., Inc.
  12. Novartis Research Foundation
  13. Swedish Agency for Innovation Systems
  14. Swedish Foundation for Strategic Research
  15. Wellcome Trust

Ask authors/readers for more resources

Guanine monophosphate (GMP) synthetase is a bifunctional two-domain enzyme. The N-terminal glutaminase domain generates ammonia from glutamine and the C-terminal synthetase domain aminates xanthine monophosphate (XMP) to form GMP. Mammalian GMP synthetases (GMPSs) contain a 130-residue-long insert in the synthetase domain in comparison to bacterial proteins. We report here the structure of a eukaryotic GMPS. Substrate XMP was bound in the crystal structure of the human GMPS enzyme. XMP is bound to the synthetase domain and covered by a LID motif. The enzyme forms a dimer in the crystal structure with subunit orientations entirely different from the bacterial counterparts. The inserted sub-domain is shown to be involved in substrate binding and dimerization. Furthermore, the structural basis for XMP recognition is revealed as well as a potential allosteric site. Enzymes in the nucleotide metabolism typically display an increased activity in proliferating cells due to the increased need for nucleotides. Many drugs used as immunosuppressants and for treatment of cancer and viral diseases are indeed nucleobase- and nucleoside-based compounds, which are acting on or are activated by enzymes in this pathway. The information obtained from the crystal structure of human GMPS might therefore aid in understanding interactions of nucleoside-based drugs with GMPS and in structure-based design of GMPS-specific inhibitors. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available